{"url_path":"/sec/lfmd/8-k/2026-06-22/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure**.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/948320/0001493152-26-029503-index.html","accession_number":"0001493152-26-029503","cik":"0000948320","ticker":"LFMD","issuer_name":"LifeMD, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/948320/0001493152-26-029503-index.html","primary_entity_key":"0000948320","primary_entity_name":"LifeMD, Inc."},"word_count":701,"has_tables":true,"body_markdown":"** **\n\n**Item\n7.01 Regulation FD Disclosure**.\n\n \n\nOn\nJune 22, 2026, LifeMD, Inc. (the “Company” or “LifeMD”) announced a strategic co-marketing collaboration supporting\na direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection, the only FDA-approved once-weekly subcutaneous\ntestosterone auto-injector. The program will launch in July 2026 and will initially be available in 37 states.\n\n \n\nThe\nCompany entered into a Master Services Agreement and Statement of Work, as well as Specialty Pharmacy Services Agreements, with Antares\nPharma, Inc., a subsidiary of Halozyme, Inc., in furtherance of the strategic co-marketing collaboration. Under these agreements, the\nCompany will serve as the exclusive telehealth co-marketing partner for the XYOSTED self-pay program. Patients accessing the program\nwill be evaluated by licensed clinicians through the Company’s affiliated medical group, and the Company’s pharmacy will\nserve as the preferred dispensing pharmacy for the program, shipping XYOSTED directly to patients’ homes. The parties will collaborate\non, and jointly invest in, consumer education and promotional initiatives designed to expand awareness of testosterone deficiency and\nof the program itself.\n\n \n\nThe\nparties will establish a joint steering committee to provide strategic oversight and governance of the project and the parties’\nrespective obligations, including quarterly proposal, review and approval of co-funded marketing investments. Failure to meet budgeted\nmarketing investments for two consecutive quarters will give either party the right, but not the obligation, to terminate the Statement\nof Work.\n\n \n\nThe\nagreements have an initial term of three years with automatic renewal for successive one-year periods unless either party provides 90\ndays’ written notice of non-renewal. The agreements contain customary representations, warranties and covenants by each of the\nparties, and indemnification provisions under which the parties have agreed, subject to certain limitations, to indemnify each other\nagainst certain liabilities.\n\n \n\nOn\nJune 22, 2026, the Company issued a press release announcing the strategic co-marketing collaboration. A copy of the Company’s\npress release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.\n\n \n\nThe\nCompany makes no admission as to the materiality of any information in this Current Report on Form 8-K, including the press release,\nthat is required to be disclosed solely by reason of Regulation FD. The Company undertakes no duty or obligation to publicly update or\nrevise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes\nis warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or\nthrough other public disclosure.\n\n \n\nThe\ninformation provided under this Item 7.01 of this Current Report on Form 8-K, including the press release, is “furnished”\nand shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed\nincorporated by reference in any Company filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall\nbe expressly set forth by specific reference in such filing.\n\n \n\n**Cautionary\nStatements Regarding Forward-Looking Information**\n\n \n\nThis\nCurrent Report on Form 8-K, including the press release, contains forward-looking statements within the meaning of the Private Securities\nLitigation Reform Act of 1995, including, without limitation, statements regarding the expected launch timing, scope, pricing, and benefits\nof the XYOSTED self-pay program; the number of states in which the program will be available and any potential expansion; the parties’\nplanned promotional and consumer education initiatives; expected patient demand and access; and the anticipated benefits of the collaboration\nto patients and to each company. Words such as “expect,” “believe,” “will,” “designed to,”\n“anticipate,” and similar expressions identify forward-looking statements. These statements are based on current expectations\nand assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks related\nto the commercial launch and adoption of the program, changes in federal or state laws governing telehealth prescribing of controlled\nsubstances, regulatory and compliance requirements applicable to telehealth, pharmacy, and pharmaceutical promotion, and the other risks\ndescribed in each company’s filings with the Securities and Exchange Commission, including LifeMD’s and Halozyme’s\nmost recent Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Neither company undertakes any obligation to update\nforward-looking statements except as required by law."}